                         SEQUENCE LISTING

<110>  Georgia State University Resarch Foundation, Inc.
 
<120>  INTEGRIN-TARGETING PROTEIN AND METHODS OF USE THEREOF

<130>  2935721-1001

<140>  PCT/US16/21037
<141>  2016-03-04

<150>  62129499
<151>  2015-03-06

<160>  3     

<170>  PatentIn version 3.5

<210>  1
<211>  105
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Segment of Wild-type CD2

<400>  1

Lys Glu Ile Thr Asn Ala Leu Glu Thr Trp Gly Ala Leu Gly Gln Asp 
1               5                   10                  15      


Ile Asn Leu Asp Ile Pro Ser Phe Gln Met Ser Asp Asp Ile Asp Asp 
            20                  25                  30          


Ile Lys Trp Glu Lys Thr Ser Asp Lys Lys Lys Ile Ala Gln Phe Arg 
        35                  40                  45              


Lys Glu Lys Glu Thr Phe Lys Glu Lys Asp Thr Tyr Lys Leu Phe Lys 
    50                  55                  60                  


Asn Gly Thr Leu Lys Ile Lys His Leu Lys Thr Asp Asp Gln Asp Ile 
65                  70                  75                  80  


Tyr Lys Val Ser Ile Tyr Asp Thr Lys Gly Lys Asn Val Leu Glu Lys 
                85                  90                  95      


Ile Phe Asp Leu Lys Ile Gln Glu Arg 
            100                 105 


<210>  2
<211>  105
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  man-made sequence

<400>  2

Lys Glu Ile Thr Asn Ala Leu Glu Thr Trp Gly Ala Leu Gly Gln Asp 
1               5                   10                  15      


Ile Asn Leu Asp Ile Pro Ser Phe Gln Met Ser Asp Asp Ile Asp Asp 
            20                  25                  30          


Ile Lys Trp Glu Lys Thr Ser Asp Lys Lys Lys Ile Ala Gln Phe Arg 
        35                  40                  45              


Lys Glu Lys Glu Thr Phe Lys Glu Lys Asp Thr Tyr Lys Leu Phe Lys 
    50                  55                  60                  


Asn Gly Thr Leu Lys Ile Lys His Leu Lys Thr Asp Asp Gln Asp Ile 
65                  70                  75                  80  


Tyr Lys Val Ser Ile Tyr Asp Thr Lys Gly Lys Asn Val Asn Asp Val 
                85                  90                  95      


Cys Asn Phe Ala Ser Arg Gln Glu Arg 
            100                 105 


<210>  3
<211>  105
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Man-made Sequence

<400>  3

Lys Glu Ile Thr Asn Ala Leu Glu Thr Trp Gly Ala Leu Gly Gln Asp 
1               5                   10                  15      


Ile Asn Leu Asp Ile Pro Ser Phe Gln Met Ser Asp Asp Ile Asp Asp 
            20                  25                  30          


Ile Lys Trp Glu Lys Thr Ser Asp Lys Lys Lys Ile Ala Gln Phe Arg 
        35                  40                  45              


Lys Glu Lys Glu Thr Phe Lys Glu Lys Asp Thr Tyr Lys Leu Phe Lys 
    50                  55                  60                  


Asn Gly Thr Leu Lys Ile Lys His Leu Lys Thr Asp Asp Gln Asp Ile 
65                  70                  75                  80  


Tyr Lys Val Ser Ile Tyr Asp Thr Lys Gly Lys Asn Val Leu Glu Lys 
                85                  90                  95      


Tyr Asp Tyr Leu Lys Ile Gln Glu Arg 
            100                 105 


